GSK (NYSE:GSK) Issues FY 2026 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 4.900-5.000 for the period, compared to the consensus earnings per share estimate of 4.790. The company issued revenue guidance of $44.8 billion-$44.8 billion, compared to the consensus revenue estimate of $45.7 billion. GSK also updated its FY 2031 guidance to EPS.

GSK Stock Up 1.2%

Shares of GSK stock opened at $51.97 on Tuesday. The stock has a market capitalization of $105.11 billion, a P/E ratio of 13.50, a PEG ratio of 3.27 and a beta of 0.35. The company has a quick ratio of 0.52, a current ratio of 0.79 and a debt-to-equity ratio of 0.80. The stock has a 50 day moving average price of $51.62 and a two-hundred day moving average price of $53.43. GSK has a 12-month low of $36.75 and a 12-month high of $61.69.

GSK (NYSE:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $0.67 EPS for the quarter, missing the consensus estimate of $1.27 by ($0.60). GSK had a net margin of 17.82% and a return on equity of 44.28%. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts expect that GSK will post 4.84 earnings per share for the current year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, July 9th. Investors of record on Friday, May 15th were paid a $0.44 dividend. The ex-dividend date was Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a yield of 3.4%. GSK’s dividend payout ratio (DPR) is presently 46.49%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on GSK. HSBC upgraded shares of GSK from a “reduce” rating to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group upgraded shares of GSK to a “strong-buy” rating in a report on Friday, July 17th. Weiss Ratings downgraded GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th. Citigroup started coverage on GSK in a research note on Friday. They issued a “neutral” rating on the stock. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GSK has an average rating of “Hold” and a consensus target price of $53.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Triumph Capital Management acquired a new position in shares of GSK during the third quarter valued at about $40,000. SkyView Investment Advisors LLC bought a new position in GSK during the fourth quarter valued at about $302,000. Gabelli Funds LLC increased its stake in GSK by 17.8% during the second quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company’s stock valued at $306,000 after acquiring an additional 1,200 shares during the period. IHT Wealth Management LLC raised its holdings in GSK by 12.1% in the 2nd quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company’s stock valued at $566,000 after acquiring an additional 1,589 shares in the last quarter. Finally, Brighton Jones LLC acquired a new position in GSK in the 4th quarter valued at approximately $528,000. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.